Psoriatic arthritis: A quantitative overview of therapeutic options

British Journal of Rheumatology

Volumn 36, Issue 1, 1997, Pages 95-99

  Jones, G ^a   Crotty, M ^b   Brooks, P ^b  

^a The Menzies Foundation   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Meta analysis; Psoriatic arthritis; Treatment

Indexed keywords

AURANOFIN; AZATHIOPRINE; CEFTRIAXONE; COLCHICINE; ETRETINATE; FUMARIC ACID; GAMMA INTERFERON; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0030753980     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Wright V, Moll MH. Seronegative polyarthritis. Amsterdam: North Holland Publishing Co., 1976.
2. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalised for psoriasis. Mayo Clin Proc 1978;53:511-8.
3. Roberts MCT, Wright V, Hill AGS, Mehra AC. Psoriatic arthritis: a follow-up study. Ann Rheum Dis 1976;35:206-12.
4. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell MC. Longterm study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
5. Dorwart BB, Gall EP, Schumacher HR et al. Chrysotherapy in psoriatic arthritis: efficacy and toxicity compared to rheumatoid arthritis. Arthritis Rheum 1978;21:513-5.
6. Wilson A, Henry DA. Meta-analysis. Part 2: Assessing the quality of published meta-analyses. Med J Aust 1992;156:173-87.
7. Tugwell P, Boers M. OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials: conclusion. J Rheumatol 1993;20:590.
8. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of a pooled index. J Rheumatol 1993;20:575-8.
9. Fleiss JL. The statistical basis of meta-analysis. Statist Methods Med Res 1993;2:121-45.
10. Black RL, O'Brien WM, Van Scott EJ et al. Methotrexate therapy in psoriatic arthritis. J Am Med Assoc 1964;189:743-7.
11. Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum 1972;15:116-7.
12. Willkens RE, Williams J, Ward JR, Egger MJ et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
13. Hopkins R, Bird HA, Jones H, Hill J et al. A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Ann Rheum Dis 1985;44:189-93.
14. Price R, Gibson T. D-Penicillamine and psoriatic arthropathy. Br J Rheumatol 1986;24:228.
15. Seideman P, Fjellner B, Johannesson A. Psoriatic arthritis treated with oral colchicine. J Rheumatol 1987;14:777-9.
16. Carette S, Calin A, McCafferty JP, Wallin BA and The Auranofin Cooperating Group. A double-blind placebo-controlled with psoriatic arthritis. Arthritis Rheum 1989;32:158-65.
17. Caperton EM, Heim-Duthoy KL, Matzke GR. Ceftriaxone therapy of chronic inflammatory arthritis. A double-blind placebo controlled trial. Arch Intern Med 1990;150:1677-82.
18. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 1990;95:138S-41S.
19. Farr M, Kitas GD, Waterhouse L et al. Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1990;29:46-9.
20. Palit J, Hill J, Capell HA, Carey J et al. A multicentre double-blind comparison of auranofin intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990;29:280-3.
21. Peeters AJ, Dijkmans BA, van der Schroeff JG. Fumaric acid therapy for psoriatic arthritis. A randomised, double-blind, placebo-controlled study [Letter]. Br J Rheumatol 1992;31:502-3.
22. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. Br J Rheumatol 1993;32:923-5.
23. McKendry RJR, Kraag G, Seigel S, Awadhi AA. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993;52:826-8.
24. Clegg DO, Reda DJ. Comparison of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthritis Rheum 1994;37(suppl. 1):S206.
25. Combe B, Goupille P, Kuntz JL et al. Sulfasalazine in psoriatic arthritis: a randomized multicentre placebo-controlled study. Arthritis Rheum 1994;37(suppl. 1):S207.
26. Dougados M, van der Linden S, Leirisalo-Repo M. Sulfasalazine in the treatment of spondylarthropathy: a randomized multicentre, double blind placebo-controlled study. Arthritis Rheum 1995;38:618-27.
27. Bruckle W, Dexel T, Grasedyck K, Schattenkirchner M. Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 1994;13: 209-16.
28. Veale DJ, Torley HI, Richards IM et al. A double-blind placebo controlled trial of efamol marine on skin and joint symptoms of psoriatic arthritis. Br J Rheumatol 1994;33:945-8.
29. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-61.